Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
12
ENVB Quote, Financials, Valuation and Earnings
Last price:
$2.33
Seasonality move
:
-1.13%
Day range:
$2.14 - $2.59
52-week range:
$2.14 - $54.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.02x
P/B ratio:
0.36x
Volume:
84.3K
Avg. volume:
65K
1-year change:
-88.24%
Market cap:
$1.2M
Revenue:
--
EPS (TTM):
-$81.48
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ENVB
Enveric Biosciences, Inc.
|
-- | -$0.55 | -- | -60% | $10.00 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$298.6M | $0.20 | 13.44% | 28.72% | $31.21 |
|
ATAI
Atai Beckley, Inc.
|
$83.2K | -$0.14 | -94.65% | -25.5% | $12.27 |
|
BEAT
HeartBeam, Inc.
|
$266.7K | -- | -- | -- | $4.63 |
|
IBIO
iBio, Inc.
|
$33.3K | -$0.05 | -83.34% | -91.89% | $4.72 |
|
KTTA
Pasithea Therapeutics Corp.
|
-- | -$0.18 | -- | -92.51% | $3.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ENVB
Enveric Biosciences, Inc.
|
$2.37 | $10.00 | $1.2M | -- | $0.00 | 0% | 0.02x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$23.56 | $31.21 | $4B | 15.16x | $0.00 | 0% | 3.79x |
|
ATAI
Atai Beckley, Inc.
|
$3.77 | $12.27 | $1.4B | -- | $0.00 | 0% | 231.10x |
|
BEAT
HeartBeam, Inc.
|
$1.43 | $4.63 | $49.3M | -- | $0.00 | 0% | -- |
|
IBIO
iBio, Inc.
|
$2.42 | $4.72 | $54.4M | -- | $0.00 | 0% | 106.96x |
|
KTTA
Pasithea Therapeutics Corp.
|
$0.73 | $3.00 | $5.4M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ENVB
Enveric Biosciences, Inc.
|
-- | 1.271 | -- | 4.15x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.900 | 1.52% | 2.70x |
|
ATAI
Atai Beckley, Inc.
|
1.82% | 4.689 | 0.23% | 6.93x |
|
BEAT
HeartBeam, Inc.
|
-- | -1.677 | -- | 0.75x |
|
IBIO
iBio, Inc.
|
5.55% | 0.321 | 19.65% | 8.21x |
|
KTTA
Pasithea Therapeutics Corp.
|
0.32% | -3.621 | 0.72% | 3.07x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ENVB
Enveric Biosciences, Inc.
|
-$40.4K | -$1.9M | -322.21% | -322.21% | -- | -$2.1M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
ATAI
Atai Beckley, Inc.
|
$516K | -$28.4M | -82.97% | -91.85% | -3796.53% | -$25M |
|
BEAT
HeartBeam, Inc.
|
-$8K | -$5.3M | -555.14% | -555.14% | -- | -$3.2M |
|
IBIO
iBio, Inc.
|
-$189K | -$6M | -75.48% | -88.23% | -5951% | -$5.7M |
|
KTTA
Pasithea Therapeutics Corp.
|
-$181.5K | -$3.1M | -91.9% | -92.48% | -- | -$2.9M |
Enveric Biosciences, Inc. vs. Competitors
-
Which has Higher Returns ENVB or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -- compared to Enveric Biosciences, Inc.'s net margin of 25.76%. Enveric Biosciences, Inc.'s return on equity of -322.21% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital ENVBEnveric Biosciences, Inc.-- -$10.81 $3.5M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About ENVB or ACAD?
Enveric Biosciences, Inc. has a consensus price target of $10.00, signalling upside risk potential of 4963.29%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.21 which suggests that it could grow by 32.03%. Given that Enveric Biosciences, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Enveric Biosciences, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ENVBEnveric Biosciences, Inc.0 0 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is ENVB or ACAD More Risky?
Enveric Biosciences, Inc. has a beta of 0.298, which suggesting that the stock is 70.169% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.660, suggesting its less volatile than the S&P 500 by 33.951%.
-
Which is a Better Dividend Stock ENVB or ACAD?
Enveric Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enveric Biosciences, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ENVB or ACAD?
Enveric Biosciences, Inc. quarterly revenues are --, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. Enveric Biosciences, Inc.'s net income of -$1.9M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, Enveric Biosciences, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 15.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enveric Biosciences, Inc. is 0.02x versus 3.79x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ENVBEnveric Biosciences, Inc.0.02x -- -- -$1.9M ACADACADIA Pharmaceuticals, Inc.3.79x 15.16x $278.6M $71.8M
-
Which has Higher Returns ENVB or ATAI?
Atai Beckley, Inc. has a net margin of -- compared to Enveric Biosciences, Inc.'s net margin of -8157.28%. Enveric Biosciences, Inc.'s return on equity of -322.21% beat Atai Beckley, Inc.'s return on equity of -91.85%.
Company Gross Margin Earnings Per Share Invested Capital ENVBEnveric Biosciences, Inc.-- -$10.81 $3.5M ATAIAtai Beckley, Inc.68.89% -$0.28 $162.9M -
What do Analysts Say About ENVB or ATAI?
Enveric Biosciences, Inc. has a consensus price target of $10.00, signalling upside risk potential of 4963.29%. On the other hand Atai Beckley, Inc. has an analysts' consensus of $12.27 which suggests that it could grow by 225.54%. Given that Enveric Biosciences, Inc. has higher upside potential than Atai Beckley, Inc., analysts believe Enveric Biosciences, Inc. is more attractive than Atai Beckley, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ENVBEnveric Biosciences, Inc.0 0 0 ATAIAtai Beckley, Inc.11 0 0 -
Is ENVB or ATAI More Risky?
Enveric Biosciences, Inc. has a beta of 0.298, which suggesting that the stock is 70.169% less volatile than S&P 500. In comparison Atai Beckley, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ENVB or ATAI?
Enveric Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Atai Beckley, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enveric Biosciences, Inc. pays -- of its earnings as a dividend. Atai Beckley, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ENVB or ATAI?
Enveric Biosciences, Inc. quarterly revenues are --, which are smaller than Atai Beckley, Inc. quarterly revenues of $749K. Enveric Biosciences, Inc.'s net income of -$1.9M is higher than Atai Beckley, Inc.'s net income of -$61.1M. Notably, Enveric Biosciences, Inc.'s price-to-earnings ratio is -- while Atai Beckley, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enveric Biosciences, Inc. is 0.02x versus 231.10x for Atai Beckley, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ENVBEnveric Biosciences, Inc.0.02x -- -- -$1.9M ATAIAtai Beckley, Inc.231.10x -- $749K -$61.1M
-
Which has Higher Returns ENVB or BEAT?
HeartBeam, Inc. has a net margin of -- compared to Enveric Biosciences, Inc.'s net margin of --. Enveric Biosciences, Inc.'s return on equity of -322.21% beat HeartBeam, Inc.'s return on equity of -555.14%.
Company Gross Margin Earnings Per Share Invested Capital ENVBEnveric Biosciences, Inc.-- -$10.81 $3.5M BEATHeartBeam, Inc.-- -$0.15 $406K -
What do Analysts Say About ENVB or BEAT?
Enveric Biosciences, Inc. has a consensus price target of $10.00, signalling upside risk potential of 4963.29%. On the other hand HeartBeam, Inc. has an analysts' consensus of $4.63 which suggests that it could grow by 223.43%. Given that Enveric Biosciences, Inc. has higher upside potential than HeartBeam, Inc., analysts believe Enveric Biosciences, Inc. is more attractive than HeartBeam, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ENVBEnveric Biosciences, Inc.0 0 0 BEATHeartBeam, Inc.2 1 0 -
Is ENVB or BEAT More Risky?
Enveric Biosciences, Inc. has a beta of 0.298, which suggesting that the stock is 70.169% less volatile than S&P 500. In comparison HeartBeam, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ENVB or BEAT?
Enveric Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. HeartBeam, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enveric Biosciences, Inc. pays -- of its earnings as a dividend. HeartBeam, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ENVB or BEAT?
Enveric Biosciences, Inc. quarterly revenues are --, which are smaller than HeartBeam, Inc. quarterly revenues of --. Enveric Biosciences, Inc.'s net income of -$1.9M is higher than HeartBeam, Inc.'s net income of -$5.3M. Notably, Enveric Biosciences, Inc.'s price-to-earnings ratio is -- while HeartBeam, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enveric Biosciences, Inc. is 0.02x versus -- for HeartBeam, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ENVBEnveric Biosciences, Inc.0.02x -- -- -$1.9M BEATHeartBeam, Inc.-- -- -- -$5.3M
-
Which has Higher Returns ENVB or IBIO?
iBio, Inc. has a net margin of -- compared to Enveric Biosciences, Inc.'s net margin of -5720%. Enveric Biosciences, Inc.'s return on equity of -322.21% beat iBio, Inc.'s return on equity of -88.23%.
Company Gross Margin Earnings Per Share Invested Capital ENVBEnveric Biosciences, Inc.-- -$10.81 $3.5M IBIOiBio, Inc.-189% -$0.11 $59.3M -
What do Analysts Say About ENVB or IBIO?
Enveric Biosciences, Inc. has a consensus price target of $10.00, signalling upside risk potential of 4963.29%. On the other hand iBio, Inc. has an analysts' consensus of $4.72 which suggests that it could grow by 95.04%. Given that Enveric Biosciences, Inc. has higher upside potential than iBio, Inc., analysts believe Enveric Biosciences, Inc. is more attractive than iBio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ENVBEnveric Biosciences, Inc.0 0 0 IBIOiBio, Inc.5 0 0 -
Is ENVB or IBIO More Risky?
Enveric Biosciences, Inc. has a beta of 0.298, which suggesting that the stock is 70.169% less volatile than S&P 500. In comparison iBio, Inc. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.829%.
-
Which is a Better Dividend Stock ENVB or IBIO?
Enveric Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enveric Biosciences, Inc. pays -- of its earnings as a dividend. iBio, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ENVB or IBIO?
Enveric Biosciences, Inc. quarterly revenues are --, which are smaller than iBio, Inc. quarterly revenues of $100K. Enveric Biosciences, Inc.'s net income of -$1.9M is higher than iBio, Inc.'s net income of -$5.7M. Notably, Enveric Biosciences, Inc.'s price-to-earnings ratio is -- while iBio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enveric Biosciences, Inc. is 0.02x versus 106.96x for iBio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ENVBEnveric Biosciences, Inc.0.02x -- -- -$1.9M IBIOiBio, Inc.106.96x -- $100K -$5.7M
-
Which has Higher Returns ENVB or KTTA?
Pasithea Therapeutics Corp. has a net margin of -- compared to Enveric Biosciences, Inc.'s net margin of --. Enveric Biosciences, Inc.'s return on equity of -322.21% beat Pasithea Therapeutics Corp.'s return on equity of -92.48%.
Company Gross Margin Earnings Per Share Invested Capital ENVBEnveric Biosciences, Inc.-- -$10.81 $3.5M KTTAPasithea Therapeutics Corp.-- -$0.41 $12.2M -
What do Analysts Say About ENVB or KTTA?
Enveric Biosciences, Inc. has a consensus price target of $10.00, signalling upside risk potential of 4963.29%. On the other hand Pasithea Therapeutics Corp. has an analysts' consensus of $3.00 which suggests that it could grow by 313.79%. Given that Enveric Biosciences, Inc. has higher upside potential than Pasithea Therapeutics Corp., analysts believe Enveric Biosciences, Inc. is more attractive than Pasithea Therapeutics Corp..
Company Buy Ratings Hold Ratings Sell Ratings ENVBEnveric Biosciences, Inc.0 0 0 KTTAPasithea Therapeutics Corp.1 0 0 -
Is ENVB or KTTA More Risky?
Enveric Biosciences, Inc. has a beta of 0.298, which suggesting that the stock is 70.169% less volatile than S&P 500. In comparison Pasithea Therapeutics Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ENVB or KTTA?
Enveric Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pasithea Therapeutics Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enveric Biosciences, Inc. pays -- of its earnings as a dividend. Pasithea Therapeutics Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ENVB or KTTA?
Enveric Biosciences, Inc. quarterly revenues are --, which are smaller than Pasithea Therapeutics Corp. quarterly revenues of --. Enveric Biosciences, Inc.'s net income of -$1.9M is higher than Pasithea Therapeutics Corp.'s net income of -$3M. Notably, Enveric Biosciences, Inc.'s price-to-earnings ratio is -- while Pasithea Therapeutics Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enveric Biosciences, Inc. is 0.02x versus -- for Pasithea Therapeutics Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ENVBEnveric Biosciences, Inc.0.02x -- -- -$1.9M KTTAPasithea Therapeutics Corp.-- -- -- -$3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
53
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 30x
Alerts
Sell
40
BILL alert for Feb 7
Bill Holdings, Inc. [BILL] is up 37.11% over the past day.
Buy
75
PRLB alert for Feb 7
Proto Labs, Inc. [PRLB] is up 28.33% over the past day.
Sell
30
MSTR alert for Feb 7
Strategy, Inc. [MSTR] is up 26.08% over the past day.
